The story of copyright's flagship drug presents a nuanced case for investors in the pharmaceutical sector. While initially a phenomenal success, producing vast sums, the exclusivity lapse and the subsequent arrival of https://pharma325262.alltdesign.com/sildenafil-and-pharma-a-risky-play-60501811